Pfizer (PFE)
(Delayed Data from NYSE)
$28.58 USD
-0.22 (-0.76%)
Updated Jun 7, 2024 04:01 PM ET
After-Market: $28.55 -0.03 (-0.10%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PFE 28.58 -0.22(-0.76%)
Will PFE be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for PFE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PFE
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug
PFE: What are Zacks experts saying now?
Zacks Private Portfolio Services
FDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains
GSK Stock Dips on Delaware Court Ruling for Zantac Litigation
Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine
Other News for PFE
Masters In Trading - Saturday, June 8
GSK wins FDA nod to expand label for RSV vaccine
Dividend Champion, Contender, And Challenger Highlights: Week Of June 9
IXJ: Growth Expected To Be Very Strong In The Next Few Years
FDA selects JN.1 variant for next COVID vaccine campaign